BEIJING, April 2, 2025 /PRNewswire/ -- Autohome Inc. (NYSE:ATHM, HKEX: 2518)) ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today issued its 2024 Environmental, Social and Governance ("ESG") report. The report outlines Autohome's comprehensive long-term ESG strategy, progress it has made in key areas including corporate governance, product responsibility, responsible management practices, talent development, sustainable operations, and impactful social welfare initiatives. Mr. Quan Long, Chairman of Autohome, commented, "As we continue to drive innovation and growth, we remain firmly committed to fostering a sustainable automotive ecosystem

2 April 2025, 10:30 CET ArcelorMittal (the "Company") today announces that it has completed the 85 million shares buyback program it announced on 5 May 2023 under the authorization given by the annual general meeting of shareholders of 2 May 2023 and continued under the 30 April 2024 annual general meeting of shareholders authorization. By market close on 1 April 2025, ArcelorMittal had repurchased 85 million shares. All details are available on the Company's website at: https://corporate.arcelormittal.com/investors/equity-investors/share-buyback-program. ENDS About ArcelorMittal ArcelorMittal is one of the world's leading integrated steel and mining companies with a presence in 60 coun

Leveraging Infosys Topaz, the Stats Center offers interactive and immersive stories based on driver and team stats across seasons BENGALURU, India, April 2, 2025 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE:INFY), a global leader in next-generation digital services and consulting, today announced the launch of the Formula E Stats Center, developed in partnership with the ABB FIA Formula E World Championship, the world's first all-electric FIA World Championship. The Stats Center is powered by Infosys Topaz, an AI-first offering using generative AI technologies, and is set to redefine fan engagement by delivering advanced, data-driven insights and immersive experiences.

Uber Technologies, Inc. (NYSE:UBER) and WeRide (NASDAQ:WRD) have taken another step toward shaping the future of mobility, announcing today a partnership with Dubai's Road and Transport Authority (RTA). The partnership paves the way for Uber to make AVs an accessible and reliable part of everyday life in Dubai, beginning with WeRide as the first technology partner. His Excellency Mattar Al Tayer, Director General, Chairman of the Board of Executive Directors of RTA, said: "This partnership with Uber, starting with WeRide as the technology partner, represents a crucial step in advancing Dubai's Self-Driving Transport Strategy, which aims to transform 25% of all journeys in the city into aut

Deutsche Bank downgraded Altria from Buy to Hold

HSBC Securities upgraded Lloyds Banking from Hold to Buy

CJS Securities initiated coverage of Hawkins with a rating of Market Outperform and set a new price target of $125.00

Stephens initiated coverage of Zscaler with a rating of Overweight and set a new price target of $255.00

4 - PATRIOT NATIONAL BANCORP INC (0001098146) (Issuer)

4/A - EAGLE BANCORP INC (0001050441) (Issuer)

4 - INTELLINETICS, INC. (0001081745) (Issuer)

4 - Petco Health & Wellness Company, Inc. (0001826470) (Issuer)

4 - HEALTHCARE SERVICES GROUP INC (0000731012) (Issuer)

4 - HEALTHCARE SERVICES GROUP INC (0000731012) (Issuer)

4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

SCHEDULE 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

SCHEDULE 13D/A - Lamb Weston Holdings, Inc. (0001679273) (Subject)

SCHEDULE 13G - CoreWeave, Inc. (0001769628) (Subject)

SCHEDULE 13G - CalciMedica, Inc. (0001534133) (Subject)

For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

New Managing Director for iPipeline UK will join the Executive Leadership Team in shaping future growth strategies iPipeline®, a leading provider of digital solutions for the life insurance and wealth management industries, announces the appointment of Rachel Edwards as Managing Director, UK. The former Verisk Global Managing Director will guide iPipeline's UK business strategy and product roadmap, supporting its mission to simplify, transform, and connect the protection and pensions savings & investment markets. Edwards joins iPipeline on April 14 and will oversee a seven-person leadership team in the UK. She will report directly to CEO Pat O'Donnell. Edwards brings a 20-year track recor

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

Jason Short rejoins the bank to lead financial sponsor client coverage on the West Coast Barclays today announces the appointment of Jason Short as a Managing Director in the Financial Sponsors Group (FSG), based in San Francisco and covering West Coast accounts. Expanding the capabilities with financial sponsor clients is key to the growth of Barclays' Investment Banking business. In his new role, Jason will be responsible for building and maintaining relationships with financial sponsor clients based on the West Coast and their portfolio company management teams. Jason's hire is part of Barclays' strategic investment in our sponsors practice and follows the announcement of Isobel van Da

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (TSX:CIGI, NASDAQ:CIGI) ("Colliers" or the "Company") today announced that at its annual meeting of shareholders held virtually on April 1, 2025, the ten director nominees listed in Colliers' management information circular dated February 13, 2025 (the "Circular") were elected as directors of Colliers. Directors have been elected to serve until the close of the next annual meeting of shareholders. The detailed results of the vote are set out below. NomineeVotes For% Votes ForVotes Withheld% Votes WithheldJohn (Jack) P. Curtin, Jr.69,752,92699.01%699,8830.99%P. Jane Gavan54,954,89678.00%15,497,91322.00%Stephen J.

ST HELIER, Jersey, April 02, 2025 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("the Company" or "Caledonia") (NYSE AMERICAN, AIM and VFEX: CMCL) announces that, pursuant to the vesting of awards made under the 2015 Omnibus Equity Incentive Compensation Plan of the Company (the "Plan") and following the publication of financial results for the year ended December 31, 2024, a total of 80,230 common shares of no par value in the Company are being issued on or about April 4, 2025 to members of staff within the Company's group, including in the form of depositary interests and Zimbabwe depositary receipts in respect of such shares (together the "Securities"). The following "Persons Di

Light & Wonder, Inc. (NASDAQ and ASX: LNW) ("Light & Wonder" or the "Company"), announced today it will host an update call regarding the Dragon Train litigation on Wednesday, April 2, 2025, after market close. The investor conference call and simultaneous webcast will be hosted at 4:30 p.m. U.S. Eastern Time. Participants are encouraged to pre-register for the conference call by using the following link. To pre-register, click here: Light & Wonder Litigation Conference Call Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to the call start

Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 4/1/2025 Ex-Date- 4/15/2025 Record- 4/15/2025 Payable- 5/1/2025   Ticker Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*  BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municip

In accordance with the RiverNorth closed-end funds (the "Funds") level distribution policies, the Funds have established the distribution dates for April, May and June 2025. The payment of the distributions are subject to Board approval. Ex Date Record Date Payable Date 4/15/2025 4/15/2025 4/30/2025 5/15/2025 5/15/2025 5/30/2025 6/13/2025 6/13/2025 6/30/2025 Tax-Exempt Distributions1 Fund Name Ticker Distribution Per Share Net Asset Value (NAV) as of 3/31/2025 Annualized Current Distribution Rate at NAV Market Price as of 3/31/2025 Annualized Current Distribution Rate at Market Inception to Date Cumulative Distributions^

SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

SC 13D/A - INCOME OPPORTUNITY REALTY INVESTORS INC /TX/ (0000949961) (Subject)

SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

SC 13D - Neuronetics, Inc. (0001227636) (Subject)

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan